Aligos licenses Hep B drug to Amoytop for $25M

Aligos Therapeutics, Inc. entered a regional license agreement with Xiamen Amoytop Biotech for its investigational Hepatitis B therapy pevifoscorvir sodium.

Rhea-AI Filing Summary

Aligos Therapeutics, Inc. entered a regional license agreement with Xiamen Amoytop Biotech for its investigational Hepatitis B therapy pevifoscorvir sodium. Amoytop receives exclusive rights to develop, manufacture and commercialize the drug in mainland China, Taiwan, Hong Kong and Macau.

Aligos will receive an upfront cash payment of $25 million, and may earn up to $420 million in additional development, regulatory and commercial milestones, plus tiered high single-digit royalties on net sales. Amoytop will fund and lead development, regulatory work, manufacturing and commercialization in the territory, while both parties share certain data and intellectual property under perpetual, largely royalty-free cross-licenses.

Positive

• Aligos secured a non-dilutive regional deal for its Hepatitis B candidate with a $25 million upfront payment and up to $420 million in milestones plus royalties, potentially strengthening its cash position and validating the asset.
• Development, regulatory, manufacturing and commercialization responsibilities and costs in the licensed territory shift to Amoytop, allowing Aligos to focus resources on other programs and geographies while still participating in future economics.

Negative

• None.

Insights

Biopharma partnerships analyst

Aligos secures non-dilutive China partnership with meaningful upfront and milestone potential.

Aligos granted Amoytop an exclusive license for its Hepatitis B candidate in mainland China, Taiwan, Hong Kong and Macau. The deal brings an immediate $25 million cash payment, which is non-dilutive and helps fund broader development without issuing new equity.

Beyond the upfront, Aligos is eligible for up to $420 million in development, regulatory and commercial milestones, plus tiered high single-digit royalties on net sales in the territory. Actual milestone realization depends on Amoytop achieving development, approval and sales targets specified in the agreement.

Amoytop assumes development, regulatory, manufacturing and commercialization costs in the territory, while Aligos retains rights elsewhere and gains access to Amoytop’s arising intellectual property for capsid assembly modulator products outside the territory. Effectiveness depends on Amoytop shareholder approval within 45 days, so subsequent disclosures will clarify timing and early execution progress.

8-K Event Classification

Item 1.01 — Entry into a Material Definitive Agreement

1 item

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Key Figures

Upfront payment: $25 million Milestone potential: Up to $420 million Royalty rate: Tiered high single-digit +4 more

7 metrics

Upfront payment $25 million Cash payment from Amoytop to Aligos under the license agreement

Milestone potential Up to $420 million Future development, regulatory and commercial milestones payable to Aligos

Royalty rate Tiered high single-digit Royalties on net sales of the licensed product in the territory

Shareholder approval deadline 45 days Agreement terminates if Amoytop approval not received within 45 days of execution

Expected approval timing 30 days Company expects Amoytop shareholder approval within 30 days of signing

Royalty term minimum 10 years At least 10 years after first commercial sale in each region, subject to patent and exclusivity

Right of negotiation period 7 years Period during which Amoytop has negotiation rights for certain new formulations in the territory

Key Terms

exclusive, non-transferable, royalty-bearing license, Field, Territory, capsid assembly modulator products, +2 more

6 terms

exclusive, non-transferable, royalty-bearing license financial

"entered into a License Agreement ... grants to Amoytop an exclusive, non-transferable, royalty-bearing license"

Field financial

"in the field of the treatment, prevention or palliation of Hepatitis B virus infection in humans"

Territory financial

"in the territory of mainland China, Taiwan, and the Special Administrative Regions of Hong Kong and Macau"

capsid assembly modulator products technical

"to exploit any Company-controlled capsid assembly modulator products (“CAM Products”) outside the Territory"

commercially reasonable efforts financial

"Amoytop agrees to use commercially reasonable efforts to develop, manufacture, seek regulatory approval"

force majeure regulatory

"failure to meet certain milestones within agreed time limits (other than due to force majeure)"

Force majeure is a legal concept that refers to unexpected events beyond anyone’s control, such as natural disasters, war, or severe disruptions, that prevent a party from fulfilling their obligations. It matters to investors because it can delay or cancel agreements, affecting the timing and certainty of financial transactions and obligations. Essentially, it acts as a shield for parties facing unforeseen, uncontrollable problems.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aligos Therapeutics (ALGS) announce in this 8-K filing?

Aligos announced a license agreement granting Xiamen Amoytop Biotech exclusive rights to develop, manufacture and commercialize its investigational Hepatitis B therapy pevifoscorvir sodium in mainland China, Taiwan, Hong Kong and Macau, in exchange for upfront, milestone and royalty payments.

How much upfront cash does Aligos Therapeutics (ALGS) receive from Amoytop?

Aligos will receive an upfront cash payment of $25 million from Amoytop. This non-dilutive funding is tied to granting exclusive territorial rights for pevifoscorvir sodium and helps support Aligos’s operations and development activities without issuing additional equity.

What is the total milestone potential in the Aligos–Amoytop license deal?

Aligos is eligible to receive up to $420 million in future development, regulatory and commercial milestone payments from Amoytop. These milestones depend on progress of pevifoscorvir sodium, including clinical achievements, regulatory approvals and commercial performance in the licensed territory.

What royalty terms did Aligos Therapeutics (ALGS) negotiate with Amoytop?

Aligos will earn tiered, high single-digit royalties on net sales of the licensed product in the territory. Royalty obligations in each region continue until the later of 10 years after first commercial sale, patent expiry there, or loss of regulatory exclusivity for the product.

What obligations does Amoytop have under the license with Aligos Therapeutics (ALGS)?

Amoytop is responsible for development, regulatory activities, manufacturing and commercialization of the licensed product in the field and territory, at its own cost. It must use commercially reasonable efforts to develop, seek approvals, commercialize and maximize sales, and meet specified milestones.

When does the Aligos–Amoytop license agreement become effective?

The license agreement becomes effective once Amoytop’s shareholders approve the transaction, which is expected within 30 days of signing. If shareholder approval is not obtained within 45 days after execution, the agreement terminates automatically under the stated conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/21/2026 - 04:32 PM Learn about SEC filing dates

false 0001799448 0001799448 2026-04-16 2026-04-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 16, 2026

Aligos Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39617		82-4724808
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

One Corporate Dr., 2nd Floor South San Francisco, CA		94080
(Address of principal executive offices)		(Zip Code)

(800) 466-6059

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		ALGS		The Nasdaq Stock Market LLC
				(Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

On April 16, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Xiamen Amoytop Biotech Co., Ltd. (“Amoytop”), pursuant to which the Company grants to Amoytop an exclusive, non-transferable, royalty-bearing license, under certain Company-controlled intellectual property, to manufacture, develop and commercialize the Company’s investigational compound pevifoscorvir sodium in its current dosage form, formulation, and mode of administration (the “Licensed Product”) in the field of the treatment, prevention or palliation of Hepatitis B virus infection in humans, or Hepatitis B virus and Hepatitis D virus co-infection in humans (the “Field”), in the territory of mainland China, Taiwan, and the Special Administrative Regions of Hong Kong and Macau (the “Territory”). Amoytop has the right to have the Licensed Product made in the Territory by manufacturers meeting certain criteria, and to sublicense its rights, subject to certain restrictions. The Company retains the right to manufacture and develop the Licensed Product in the Territory for use outside of the Territory, and for use inside the Territory outside the Field. The license grant is subject to reservation of certain rights of the Company’s licensor (Emory University, or “Emory”) of a portion of the licensed intellectual property, and subject to the terms and conditions of the Company’s license agreement with Emory. Amoytop does not have the right to modify the structure or function of the Licensed Product. Any improvement made by Amoytop to manufacturing processes, analytical methods, formulation techniques or other operational know-how is owned by Amoytop and subject to a non-exclusive, perpetual, royalty-free license to the Company for use outside the Territory, and to use, make and have made products in the Territory for sale solely outside the Territory or Field.

The effectiveness of the License Agreement is conditioned upon Amoytop’s receipt of approval of the transaction at a meeting of its shareholders, which the Company expects to occur within 30 days of signing. The License Agreement will become effective automatically upon receipt of such approval and will terminate automatically if such approval is not received within 45 days after execution.

Under the terms of the License Agreement, Amoytop is to make an upfront cash payment to the Company of $25 million. Additionally, the Company will be eligible to receive future development, regulatory and commercial milestones totaling up to $420 million, along with tiered, high single-digit royalties on net sales in the Territory. The Company’s royalty obligations continue with respect to each region in the Territory until the later of (i) ten (10) years after the first commercial sale of the Licensed Product in such region, (ii) expiration of patents claiming the Licensed Product in such region, or (iii) loss of regulatory exclusivity for the Licensed Product in such region. In the event that Amoytop enters into a commercial sublicense, Amoytop is to pay to the Company a percentage of license issue fees, other upfront licensing fees and milestone fees received by Amoytop under such sublicense.

For a period of seven (7) years from the effective date of the License Agreement, the Company agrees to notify Amoytop if it develops a novel formulation or compound containing the same active ingredient as the Licensed Product that the Company intends to offer a license in the Field in the Territory to any third party. Amoytop would have a time-limited right to enter into good faith negotiations with the Company for an exclusive, royalty-bearing license to such compound in the Field in the Territory.

Under the terms of the License Agreement, Amoytop takes responsibility for development, regulatory activities, manufacturing and commercialization of the Licensed Product in the Field and Territory during the term of the License Agreement, at its cost. The parties will assemble a joint steering committee and a joint development committee to provide guidance on such activities. The Company will conduct a technical transfer as required by the terms of the License Agreement, at Amoytop’s cost. Amoytop agrees to use commercially reasonable efforts to develop, manufacture, seek regulatory approval, commercialize and maximize sales of the Licensed Product in the Field and in the Territory, and agrees to meet certain milestones.

Intellectual property arising from the Company’s activities under the License Agreement is included within the scope of the license granted to Amoytop under the License Agreement. Intellectual property arising from Amoytop’s activities under the License Agreement (“Amoytop Arising IP”) is licensed to the Company on an exclusive, perpetual, royalty-free basis to exploit any Company-controlled capsid assembly modulator products (“CAM Products”) outside the Territory and to conduct development and manufacturing activities on CAM Products in the Territory for use outside the Territory.

Subject to restrictions in applicable laws, the Company agrees to share with Amoytop pre-clinical and clinical raw data and CMC data comprising licensed know-how on at least a quarterly basis. Such data can be used by Amoytop in a manner consistent with its license rights and the terms and conditions of the License Agreement, including for reference in Amoytop’s regulatory filings. Additionally, subject to restrictions in applicable laws, Amoytop agrees to share with the Company on at least a quarterly basis pre-clinical and clinical raw data and CMC data generated under the License Agreement. Such data is licensed to the Company on a non-exclusive, perpetual, royalty-free basis to use for any and all purposes, including for reference in the Company’s regulatory filings.

The License Agreement remains in effect, unless terminated according to its terms, until expiration of all royalty terms. Either party may terminate the License Agreement for uncured material breach, which includes in the case of Amoytop, its failure to meet certain milestones within agreed time limits (other than due to force majeure), and matters related to legal and regulatory compliance. Either party may cause the activities under the License Agreement to be suspended for a period of time for serious safety or regulatory concerns regarding the Licensed Product in the Territory, after which the parties will refer the matter to an expert panel for a binding decision if the parties are unable to agree. Upon any termination, the licenses, rights and obligations of the parties terminate other than certain provisions that survive.

The License Agreement is not assignable other than by the Company due to a change in control of the Company or a sale or other disposition of the intellectual property licensed under the License Agreement or the Company’s business related thereto. The License Agreement contains various representations, warranties, covenants, disclaimers, limitations of liability, dispute resolution mechanisms, indemnities, insurance requirements, and other provisions customary for transactions of this nature.

The foregoing is only a summary description of the terms of the License Agreement, does not purport to be complete and is qualified in its entirety by reference to the License Agreement, which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ending June 30, 2026. The Company intends to omit certain confidential portions of the License Agreement.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the expected timing of effectiveness of the License Agreement, the potential receipt of upfront, milestone and royalty payments thereunder, and the anticipated development, manufacture, regulatory approval and commercialization of the Licensed Product in the Territory. These statements are based on the Company’s current expectations and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, including the risk that Amoytop does not obtain shareholder approval of the transaction within the time period contemplated by the License Agreement (or at all), the risk that the conditions to effectiveness of the License Agreement are not satisfied, the risk that the milestones triggering future payments are not achieved, the risk that the Licensed Product does not receive required regulatory approvals or achieve commercial success in the Territory, and the other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in any subsequent Quarterly Reports on Form 10-Q. Any forward-looking statements in this Current Report on Form 8-K speak only as of the date of this report, and the Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				ALIGOS THERAPEUTICS, INC.
Date: April 21, 2026				By:		/s/ Lesley Ann Calhoun
						Lesley Ann Calhoun
						Executive Vice President, Chief Operating Officer & Chief Financial Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB